Prospect Financial Services’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$225K Buy
5,925
+82
+1% +$3.78K 0.11% 106
2026
Q2
$280K Buy
+5,843
New +$251K 0.14% 90
2025
Q1
– Sell
-2,667
Closed -$229K – 119
2024
Q4
$229K Buy
2,667
+965
+57% +$104K 0.13% 101
2024
Q3
$203K Sell
1,702
-200
-11% -$26.7K 0.13% 101
2024
Q2
$271K Sell
1,902
-453
-19% -$60K 0.21% 63
2024
Q1
$302K Buy
2,355
+13
+0.6% +$1.55K 0.25% 59
2023
Q4
$242K Buy
+2,342
New +$232K 0.24% 61

Other funds holding NVO

Prospect Financial Services's NVO Position: Q3 2026 in Review

Prospect Financial Services increased its Novo Nordisk (NVO) stake by 1.4% in Q3 2026, buying an estimated $3.78K and bringing the position to 5,925 shares worth $225K. The position accounts for 0.11% of the portfolio, ranked #106.

Prospect Financial Services first reported a position in NVO in Q4 2023 and has held it in 7 quarters since. The position peaked at $302K in Q1 2024. 1,061 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Prospect Financial Services held 5,925 shares of Novo Nordisk worth $225K as of Q3 2026.
  • Prospect Financial Services bought 82 Novo Nordisk shares in Q3 2026, an estimated $3.78K.
  • Novo Nordisk made up 0.11% of Prospect Financial Services's portfolio in Q3 2026, its #106 holding.
  • Prospect Financial Services first reported a position in Novo Nordisk in Q4 2023 and has held it in 7 quarters since.
  • Prospect Financial Services's Novo Nordisk position peaked at $302K in Q1 2024.
  • 1,061 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Prospect Financial Services's 13F filing for Q3 2026, filed 13 Nov 2026.